Merck Transforms Through Acquisitions Ahead of Keytruda Patent Expiry

Pharmaceutical giant Merck is undergoing a transformation driven by strategic acquisitions as it prepares for the upcoming patent expiration of its top-selling cancer drug, Keytruda.